drugset
drugset / Trial / NCT02243436

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

NCT02243436 ↗

Phase 1/2 Completed 67 enrolled Spanish Lymphoma Cooperative Group Millennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial aimed to determine the Maximum Tolerable Dose of the BV in combination with ESHAP in relapsed/resistant Hodgkin Lymphona patients and to evaluate response to treatment with BV-ESHAP as salvage regimen prior to autologous stem cell transplantation.

Timeline

Start
2014-11-11
Primary completion
2019-01
Completion
2019-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Brentuximab Vedotin Monoclonal antibody 0.9 mg/kg —
Subject Brentuximab Vedotin Monoclonal antibody 1.2 mg/kg —
Subject Brentuximab Vedotin Monoclonal antibody 1.8 mg/kg —
Background Cisplatin Other / unclassified 25 mg/m2 Intravenous
Background Cytarabine Small molecule 2 g Intravenous
Background Etoposide Small molecule 40 mg/m2 Intravenous
Background Methylprednisolone Other / unclassified 250 mg Intravenous

Indications

classic Hodgkin lymphoma